Select products from the Verse Originals and
Verse Concentrates lines will be available in the coming weeks
across Canada through the national
medical cannabis retail platform
KELOWNA, BC, March 17, 2021 /CNW/ - The Valens Company
Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company" or "The
Valens Company"), a leading manufacturer of cannabis
products, today announced that it will be distributing select
products from its partner Verse Cannabis ("Verse") to the
Medical Cannabis by Shoppers™ platform. Products have been
selected from each Verse Cannabis line, Verse Originals and Verse
Concentrates, which are custom manufactured by Valens and aim to
bring premium quality offerings to Canadian consumers at affordable
prices.
From the Verse Concentrates line, Medical Cannabis by
Shoppers will feature Verse Crumble, derived from an
indica-dominant White Rhino strain, with pinene, myrcene, and
caryophyllene terpenes that create a fruity and piney aroma.
Extracted with Valens' proprietary hydrocarbon method, the 1g
product features a broad spectrum of cannabinoids and has a
honeycomb-like consistency. At approximately 75-80 percent THC,
this crumble was created for an experienced consumer and comes in a
non-reactive glass container to preserve freshness. It is the first
crumble product and one of few concentrate products available in
the Medical Cannabis by Shoppers platform.
Medical Cannabis by Shoppers will also offer vape
cartridges in a variety of flavours and terpene-rich blends from
the popular Verse Originals line, including:
- Tropic Lemon, a top-selling, sativa-dominant blend inspired by
Lemon Jack and Tropic Thunder cultivars.
- Summer Berry, an indica-dominant
blend inspired by Blue Zkittles and Watermelon OG cultivars.
- Mandarin Mint, a sativa-dominant blend inspired by Tangie and
Thin Mint GSC cultivars.
- Sunset Peach, a sativa-dominant blend inspired by Peach Ozz and
Strawberry Ice cultivars.
"Since launching last year, Verse Cannabis' products have stood
out in the Canadian recreational market for their quality and price
point despite only being available at select provincial retailers.
Offering these popular products through a national cannabis retail
platform like Medical Cannabis by Shoppers gives patients across
the country increased accessibility to our partner's differentiated
product offerings," said Tyler
Robson, Chief Executive Officer, Co-Founder and Chair of The
Valens Company. "We are pleased that Medical Cannabis by Shoppers
is encouraged by the continued consumer demand we've seen for these
products with other retailers, and this rollout demonstrates the
strategic value that Valens strives to bring its partners through
its far-reaching distribution network and manufacturing
excellence."
In partnership, Valens and Verse expect to launch additional
formats on the platform, including soft chews and pre-rolls, in the
coming quarters.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis
products with a mission to bring the benefits of cannabis to the
world. The Company provides proprietary cannabis processing
services across five core technologies, in addition to
best-in-class product development, formulation and manufacturing of
cannabis consumer packaged goods. The Valens Company's high-quality
products are exclusively formulated for the medical, therapeutic,
health and wellness, and recreational consumer segments, and are
offered across numerous product formats, including oils, vapes,
concentrates, edibles and topicals, as well as pre-rolls, with a
focus on next-generation product development and innovation. Its
breakthrough patented emulsification technology, SōRSE™ by Valens,
converts cannabis oil into water-soluble emulsions for seamless
integration into a variety of product formats, allowing for
near-perfect dosing, stability, and taste. In partnership with
brand houses, consumer packaged goods companies and licensed
cannabis producers around the globe, the Company continues to grow
its diverse product portfolio in alignment with evolving cannabis
consumer preferences in key markets. Through its wholly owned
subsidiary Valens Labs Ltd., the Company is setting the standard in
cannabis testing and research and development with Canada's only ISO17025 accredited analytical
services lab, named The Centre of Excellence in Plant-Based Science
by partner and scientific world leader Thermo Fisher Scientific.
Discover more on The Valens Company and its subsidiaries at
http://www.thevalenscompany.com.
About Verse
Introducing Verse…
There is a clear need in the marketplace for Verse. On the one
hand, beautifully branded and marketed flower-based brands
line the shelves of cannabis stores nationwide. On the other hand,
quality-obsessed craft products, fill the needs of those
demanding more, but at a high price.
This is where the idea for Verse was born. An assortment
of the highest quality cannabinoid-based Gen2
products accessible to all. A brand whose North
Star would always be innovation and quality but values like
realness and honesty would trump frills and gimmicks.
Like the verse of a song or poem, where creativity follows the
rules of rhythm to become attractive to its listener, so does
Verse, combining creative innovation with the rules of
science to engineer extraordinary experiences for
consumers.
Notice regarding Forward Looking Statements
All information included in this press release, including any
information as to the future financial or operating performance and
other statements of The Valens Company that express management's
expectations or estimates of future performance, other than
statements of historical fact, constitute forward-looking
information or forward-looking statements within the meaning of
applicable securities laws and are based on expectations, estimates
and projections as of the date hereof. Forward-looking statements
are included for the purpose of providing information about
management's current expectations and plans relating to the future.
Wherever possible, words such as "plans", "expects", "scheduled",
"trends", "indications", "potential", "estimates", "predicts",
"anticipate", "to establish", "believe", "intend", "ability to", or
statements that certain actions, events or results "may", "could",
"would", "might", "will", or are "likely" to be taken, occur or be
achieved, or the negative of these words or other variations
thereof, have been used to identify such forward-looking
information. Specific forward-looking statements include, without
limitation, all disclosure regarding future results of operations,
economic conditions and anticipated courses of action. Investors
and other parties are advised that there is not necessarily any
correlation between the number of SKUs manufactured and shipped and
revenue and profit, and undue reliance should not be placed on such
information.
The risks and uncertainties that may affect
forward-looking statements include, among others, regulatory
risk, United States border
crossing and travel bans, reliance on licenses, expansion of
facilities, competition, dependence on supply of cannabis and
reliance on other key inputs, dependence on senior management and
key personnel, general business risk and liability, regulation of
the cannabis industry, change in laws, regulations and guidelines,
compliance with laws, reliance on a single facility, limited
operating history, vulnerability to rising energy costs,
unfavourable publicity or consumer perception, product liability,
risks related to intellectual property, product recalls,
difficulties with forecasts, management of growth and litigation,
many of which are beyond the control of The Valens Company. For a
more comprehensive discussion of the risks faced by The Valens
Company, and which may cause the actual financial results,
performance or achievements of The Valens Company to be materially
different from estimated future results, performance or
achievements expressed or implied by forward-looking information or
forward-looking statements, please refer to The Valens Company's
latest Annual Information Form filed with Canadian securities
regulatory authorities at www.sedar.com or on The Valens Company's
website at www.thevalenscompany.com. The risks described in such
Annual Information Form are hereby incorporated by reference
herein. Although the forward-looking statements contained herein
reflect management's current beliefs and reasonable assumptions
based upon information available to management as of the date
hereof, The Valens Company cannot be certain that actual results
will be consistent with such forward-looking information. The
Valens Company cautions you not to place undue reliance upon any
such forward-looking statements. The Valens Company disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by applicable law. Nothing herein
should be construed as either an offer to sell or a solicitation to
buy or sell securities of The Valens Company.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-valens-company-and-verse-cannabis-roll-out-products-at-medical-cannabis-by-shoppers-inc-301249641.html
SOURCE The Valens Company Inc.
